Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Psychiatry Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Psychiatry Other
    FDA Requests Boxed Warnings on Conventional Antipsychotic Drugs - (DGNews)
    Pramlintide-Related Improvements in Diabetes Benefit Patients' Psyche: Presented at ADA - (DGDispatch)
    Health Canada Approves New Treatment for Bipolar Mania - (DGNews)
    Report Confirms Increased Risk of Smoking, Substance Abuse in Bipolar Adolescents - (DGNews)
    Short-Term Antipsychotics in Older Adults With Dementia Associated With Serious Adverse Events - (DGNews)

    News archive

     Recent webcasts/CME - Psychiatry Other
    • Dementia in Hispanic Americans: The Reasons Behind the Risk
    • Prevalence and Associated Factors for Suicidal Ideation and Behaviors in Obsessive-Compulsive Disorder
      Delirium Update
      The Pharmacist's Role in Breaking the Cycle of PMDD
      Understanding Autism: The Role of the Pharmacist in the Management of Autism

      Webcasts/CME archive

       Recent cases - Psychiatry Other
        Factitious Lymphoedema as a Psychiatric Condition Mimicking Reflex Sympathetic Dystrophy: A Case Report
        Topiramate-Induced Psychosis in Two Members of the One Family: A Case Report
        Childhood Autism in a 13 Year Old Boy with Oculocutaneous Albinism: A Case Report
        Unexpected Depletion in Plasma Choline and Phosphatidylcholine Concentrations in a Pregnant Woman with Bipolar Affective Disorder Being Treated with Lithuim, Haloperidol and Benztropine: A Case Report
        Recognizing Thyrotoxicosis in a Patient with Bipolar Mania: A Case Report

        Cases archive
          




        my personal edition > psychiatry other > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Olanzapine Plus Lithium or Valproate Increases Length of Symptomatic but Not Syndromic Remission in Bipolar I Disorder

        A DGReview of :"Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone"
        British Journal of Psychiatry

        04/16/2004
        By Emma Hitt, PhD


        Addition of olanzapine to lithium or valproate appears to sustain symptomatic but not syndromic remission for a longer period compared to either lithium or valproate monotherapy, according to the findings of a new study.

        Few controlled studies have examined the use of atypical antipsychotic drugs for prevention of relapse in patients with bipolar I disorder, note Mauricio Tohen, MD, DrPH, with the Lilly Research Laboratories, Indianapolis, Indiana and colleagues.

        In their study, the researchers evaluated whether addition of olanzapine to either lithium or valproate treatment would reduce the rate of relapse compared with lithium or valproate alone.

        Participants were aged 18 to 70 years and had achieved syndromic remission after receiving olanzapine plus lithium or valproate during a 6-week double-masked study that compared combination treatment with lithium or valproate monotherapy.

        Ninety-nine patients were then randomised to receive lithium or valproate plus either olanzapine 5-20 mg/day (combination therapy) or placebo (monotherapy) and were followed for 18 months.

        During the follow-up period, time to relapse into either mania or depression was not significantly different for syndromic relapse; the median time to relapse for combination therapy was 94 days and 40.5 days for monotherapy (P = .742). However, median time to relapse was significantly longer for symptomatic relapse for combination therapy (163 days) compared to monotherapy (42 days; P = .023).

        "Our results indicate that long-term use of the combination of olanzapine plus lithium or valproate may prolong the time spent in symptomatic remission compared with lithium or valproate monotherapy in patients who have achieved remission with the combination treatment," Dr. Tohen and colleagues conclude.

        According to the researchers, the most clinically meaningful adverse event was a mean increase in body weight in the combination therapy group amounting to a gain of 2.0 kg over the 18-month relapse prevention phase, compared with a loss of 1.8 kg in the monotherapy group.

        "These findings may be useful to clinicians for evaluating the relative risks and benefits for each individual patient in determining the selection of pharmacological treatment," they suggest.

        Br J Psychiatry 2004;184:337-345. "Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone"

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send